September 22, 2011
After winning US approval in May, the new hepatitis C virus treatment telaprevir has been OK'd by EU regulators, Vertex Pharmaceuticals and Johnson & Johnson said Tuesday. J&J has European rights to the drug; Vertex, which holds exclusive US rights, will receive European royalties. The action was anticipated, given that the European Medicines Agency recommended approval in July. Sold under the brand name Incivek in the United States, telaprevir will be branded as Incivo in Europe. In studies, telaprevir administered with standard HCV treatment nearly doubled the cure rate achieved by standard treatment alone.
09.20.2011; Anand Basu
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|